This is the authors' abstract. We don't add key points for this paper.
Navigating a vast formulation-preparation design space that is highly sensitive to perturbations makes trial-and-error approaches inefficient and costly for diverse clinical needs. Here, we introduce an expert-mimic AI framework called E-MAF that integrates a process-aware surrogate with an optimized genetic algorithm to emulate coarse-to-fine reasoning, autonomously generating lab-ready designs tailored to desired release profiles. We show that E-MAF delivers on-demand release and shortens design cycles from 6-12 months to approximately 1 hour. We demonstrate that in vitro release, in vivo pharmacokinetics and therapeutic effects match or surpass commercial benchmarks across 7 active pharmaceutical ingredients. We show that E-MAF also enables release profiles that are hard to achieve by conventional approaches, exemplified by ≤2% risperidone burst within 1 h and near-zero-order release over ~28 days in vivo. These results demonstrate E-MAF’s potential to accelerate polymeric controlled-release system development and drug-delivery industrialization. Here the authors develop an AI framework called E-MAF that, starting from a desired release profile, couples process-aware prediction with expert-mimic evolutionary search to generate interpretable, lab-ready formulations for controlled release systems.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: